Key Highlights

  • Syntara Limited is a clinical-stage biotechnology company, formerly listed as Pharmaxis Ltd before a registered name change.
  • Syntara puts new emphasis on its next operational and financial milestones.
  • What is clear is that Syntara has had an active 2026.
  • Upcoming milestones will test whether the strategy translates into measurable results.

Syntara (ASX:SNT) is facing a decisive stretch as amsulostat development and upcoming study readouts define the next stage. The developments place attention on what the company has already delivered, what remains unproven and which milestones come next.

A Clinical Programme Approaches Its Next Stage

Syntara Limited is a clinical-stage biotechnology company, formerly listed as Pharmaxis Ltd before a registered name change. Its lead programme is amsulostat, a pan-LOX (lysyl oxidase) inhibitor being tested in myelofibrosis, a rare bone marrow cancer, alongside earlier-stage programmes in myelodysplastic syndrome (MDS), Parkinson's-related sleep disorder, and hypertrophic scarring. What is clear is that Syntara has had an active 2026. In April, the company announced a $10 million capital raise - an $8 million two-tranche institutional placement plus a share purchase plan - priced at $0.027 a share, which it said followed a positive 'Type C' meeting with the US FDA on the design of a planned Phase 2b myelofibrosis trial.

Amsulostat Remains the Lead Asset

That raise followed an earlier setback: in August 2025 the FDA had asked for a placebo-controlled Phase II trial and additional safety and efficacy data, which ed had roughly halved the share price at the time, before shares partly recovered on subsequent 52-week amsulostat data showing total symptom score improvement in a majority of treated patients. In July 2026, Syntara reported that its German-based AZALOX study - testing amsulostat combined with 5-azacitidine in MDS, run by the German MDS Study Group and sponsored by Heidelberg University - had cleared its first dosing cohort without dose-limiting toxicities and escalated to a final 200mg twice-daily cohort.

The company said at the time it expected preliminary Phase 1b data from that study in the fourth quarter of 2026.

Funding Supports Several Readouts

Syntara's most recent quarterly report, covering the three months to 30 June 2026 and lodged in late July 2026, disclosed a cash balance of A$13.5 million, up from A$8.9 million at 31 March 2026, with the company stating this extends its cash runway into FY2028. The company's other clinical assets - SNT-4728 in Parkinson's-related REM sleep behaviour disorder and SNT-9465 in hypertrophic scarring - were both reported to be progressing, with SNT-9465 recruitment at 60% as at that filing. Syntara operates in the high-risk, high-reward clinical biotech sector, where share prices are sensitive to trial readouts and regulatory interactions, and where none of its current programmes has yet reached a pivotal trial outcome or regulatory approval.

The Pivotal Test Is Still Ahead

The distinction between the FDA's supportive feedback on trial design - not an approval - and any future efficacy or safety findings from the planned Phase 2b study, which the company has said it aims to begin subject to funding by the end of 2026, is worth keeping in mind. Syntara has flagged several catalysts for the second half of 2026, including completed SNT-4728 data, interim results from the amsulostat MDS programme, and top-line SNT-9465 results, alongside progress toward the Phase 2b myelofibrosis trial start.

The Next Milestone

Syntara now faces its next project and financial milestones. Their delivery will show whether the latest developments translate into sustained progress, while timing and funding remain important.